Search

Your search keyword '"L, Karnström"' showing total 3 results
Start Over Author "L, Karnström" Topic age factors
3 results on '"L, Karnström"'

3. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma

Author

B. Simonsson, J. Hällen, B. Ternstedt, R. Lerner, Håkan Mellstedt, L. Engstedt, L. Karnström, Gösta Gahrton, G. Brenning, B. Lönnqvist, B. Johansson, A. Killander, Göran Holm, S.G.O. Johansson, B. Wadman, A.-M. Stalfelt, Magnus Björkholm, D. Lockner, and A. Åhre

Subjects
Melphalan, Adult, Male, medicine.medical_specialty, Urology, Drug Administration Schedule, Prednisone, medicine, Humans, Prospective Studies, Stage (cooking), Multiple myeloma, Aged, Neoplasm Staging, Clinical Trials as Topic, business.industry, Low dose, Significant difference, Age Factors, High dose melphalan, Middle Aged, medicine.disease, Surgery, Regimen, Oncology, Drug Therapy, Combination, Female, business, Multiple Myeloma, medicine.drug
Abstract

Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients). The median observation time was 59 months (range 33-84). Response to therapy was obtained in 45% of the MP group and 31% of the M group (P less than 0.05). No significant difference in response with regard to clinical stage was noted. Median survival was 36 months in the MP group and 29 months in the M group. Survival was longer in stage I and II myeloma than in the stage III cases, at least in the MP group. The median and 5-yr survival rates in stages I and II were significantly better in the MP than in the M group. Response to therapy was associated with length of survival, median survival being 62 months in responding patients and 20 months in non-responders. The MP and M groups did not differ in this respect.

Published
1983

Catalog

Books, media, physical & digital resources
See catalog results